ABBVIE INC.
ABBV XNYS
$205.20
+1.28 (+0.62%)
▲
15-min delayed
Open
$203.04
High
$206.00
Low
$201.80
Volume
6.99M
Market Cap
$362.35B
About ABBVIE INC.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| TTM 2025 | $61.16B | $4.23B | $2.37 |
| FY 2025 | $61.16B | $4.23B | $2.37 |
| Q3 2025 | $15.78B | $188.00M | $0.10 |
| Q2 2025 | $15.42B | $941.00M | $0.52 |
TickerDaily Coverage
Stock Market Today, March 24, 2026: S&P 500 Opens Higher on Jobs Data, Tech Leads Rally
Market News
Sarah Mitchell · 13h ago
The S&P 500 opened Tuesday, March 24, 2026 with solid gains as investors digested...
Stock Market Today: S&P 500 Closes Higher on Soft Inflation Data
Market News
Sarah Mitchell · Feb 24, 2026
U.S. equities finished mixed Tuesday as investors digested softer-than-expected inflation readings,...
Stock Market Today: S&P 500 Edges Higher on Fed Pivot Hopes, Tech Leads
Market News
David Brooks · Feb 23, 2026
The stock market today finished mixed as investors repositioned around inflation data and fresh Fed...
View All Coverage →
Get ABBV Alerts
Stay ahead with breaking news, price alerts, and expert analysis on ABBVIE INC..
Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.